Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
240
days
Optimizing Drug-Resistant Epilepsy Management: Cenobamate’s role in the Surgery/Neuromodulation Pathway
AuthorsGiancarlo Di Gennaro; Paolo Bonanni; Francesco Deleo; Antonio Gambardella; Roberto Michelucci; Giada Pauletto; Nicola Specchio; Alfredo D’Aniello
Affiliations1. IRCCS NEUROMED, Pozzilli, Italy; 2. IRCCS E. Medea Scientific Institute, Epilepsy Unit, Conegliano, Italy; 3. Epilepsy Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; 4. Azienda Ospedaliero-Universitaria “Renato Dulbecco” di Catanzaro, Catanzaro, Italy; 5. IRCCS-Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy; 6. SOC Neurologia, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy; 7. Neurology, Epilepsy and Movement Disorders Unit, Bambino Gesu’ Children’s Hospital, IRCCS, Full Member of European Reference Network on Rare and Complex Epilepsies, EpiCARE, Rome, Italy; 8. University Hospitals, KU Leuven, Leuven, Belgium
71
days
Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study
AuthorsSudershan Kumar; Arshad Khuroo; Sanjay Jagannath Gurule; Sachin Mehra; Hari Krishan Tiwari; Y. Zala; Venkata Rama Rao Kamala; Madhu Kandukuri; Shruti Dharmadhikari; Prashant Devkare; Chintan Khandhedia
Affiliations1. Clinical Pharmacology and Pharmacokinetics, Sun Pharmaceutical Industries Limited, Gurgaon, India; 2. Clinical Pharmacology Unit, Sun Pharmaceutical Industries Limited, Gurgaon, India; 3. Formulation Department, Sun Pharma Advanced Research Company (SPARC) Ltd, Mumbai, India; 4. Medical Affairs and Clinical Research, Sun Pharma Laboratories Limited, Mumbai, India; 5. Medical Affairs and Clinical Research, Sun Pharmaceutical Industries Limited, Mumbai, India
148
days
Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation
AuthorsSi-kai Wang; Wei Li; Miao-miao Guo; Man Han; Ze-chun Long; Jin-hui He; Xiang-yang Xie; Yuan Zeng; Hui Liu
Affiliations1. School of Pharmacy, Hubei University of Chinese Medicine, Wuhan, China; 2. Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, China; 3. Department of Pharmacy, Jingmen People’s Hospital, Jingmen, China; 4. School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, China; 5. School of Pharmacy, Hubei University of Science and Technology, Xianning, China; 6. College of Nursing and Health Management and College of Life Science and Chemistry, Wuhan Donghu University, Wuhan, China; 7. Department of Pharmacy, General Hospital of Central Theater Command, Wuhan, China
135
days
A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors
AuthorsJavier Molina-Cerrillo; Arantzazu Sierra-Ramirez; José L. López-Aceituno; Marinela Méndez-Pertuz; Teresa Alonso-Gordoa; Michael Linnebacher; Matteo Santoni; Pablo J. Fernandez-Marcos; Enrique Grande
Affiliations1. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain; 2. Metabolic Syndrome Group-BIOPROMET, Madrid Institute for Advanced Studies-IMDEA Food, CEI UAM+CSIC, Madrid, Spain; 3. CNIO Cancer Center, Madrid, Spain; 4. Department of General Surgery, Section of Molecular Oncology and Immunotherapy, University of Rostock, Rostock, Germany; 5. Medical Oncology Unit, Macerata Hospital, Macerata, Italy; 6. Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain
228
days
Ustekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies
AuthorsBolin Yang
Affiliations1. Department of Colorectal Surgery/IBD Center, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China
138
days
Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT 2C , 5-HT 2B , and 5-HT 7 Receptor Binding at Therapeutically Relevant Concentrations
AuthorsJennie Garcia-Olivares; Brittney Yegla; Jennifer Koch; Chungping Yu; Jonathan Rubin
Affiliations1. Supernus Pharmaceuticals, Inc., Rockville, USA
222
days
Arylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms
AuthorsHua Jiang; Mingzhen Xu; Songsong Jiang; Weiqiang Huang
Affiliations1. Department of Urology, The Fifth Affiliated Hospital of Zunyi Medical University (Zhuhai Sixth People’s Hospital), Zhuhai, China; 2. The Department of Biological and Pharmaceutical Sciences, Zhuhai Campus of Zunyi Medical University, Zhuhai, China
100
days
Treatment Outcomes with Lanadelumab Every 2 Weeks and Garadacimab are Very Similar in Patients with Hereditary Angioedema
AuthorsIrmgard Andresen; Natalie Khutoryansky; Sarah L. Feeny; Alissa Dangel
Affiliations1. Takeda Pharmaceuticals International AG, Zurich, Switzerland; 2. Takeda Development Center Americas, Inc., Lexington, USA; 3. Takeda Pharmaceuticals USA, Inc., Cambridge, USA
314
days
The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
AuthorsHeeJae Choi; Shilpa Madari; Elmar Daalman; Brett A. English; Atef Halabi; Kathrin Hohl; Yury Shatillo; Nathalie Weidinger; Michael Desch
Affiliations1. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USA; 2. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; 3. CRS Clinical Research Services Kiel GmbH, Kiel, Germany
187
days
Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood–Brain Barrier
AuthorsYicong Lei; Tingyu Xiao; Xin Hu; Huaqing Lin
Affiliations1. Key laboratory for Advanced Drug Delivery Systems of Guangdong Province, Guangdong Pharmaceutical University, Guangzhou, People’s Republic of China
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days